Annual Operating Expenses
$20.19 M
-$13.69 M-40.42%
31 December 2023
Summary:
ReShape Lifesciences annual total operating expenses is currently $20.19 million, with the most recent change of -$13.69 million (-40.42%) on 31 December 2023. During the last 3 years, it has risen by +$1.47 million (+7.84%). RSLS annual operating expenses is now -44.34% below its all-time high of $36.27 million, reached on 31 December 2008.RSLS Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Operating Expenses
$3.20 M
+$12.00 K+0.38%
30 September 2024
Summary:
ReShape Lifesciences quarterly total operating expenses is currently $3.20 million, with the most recent change of +$12.00 thousand (+0.38%) on 30 September 2024. Over the past year, it has dropped by -$1.19 million (-27.12%). RSLS quarterly operating expenses is now -81.31% below its all-time high of $17.12 million, reached on 30 September 2021.RSLS Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RSLS Operating Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -40.4% | -27.1% |
| 3 y3 years | +7.8% | -81.3% |
| 5 y5 years | -19.2% | -48.5% |
RSLS Operating Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -43.3% | +7.8% | -81.3% | +0.4% |
| 5 y | 5 years | -43.3% | +7.8% | -81.3% | +0.4% |
| alltime | all time | -44.3% | +81.0% | -81.3% | +0.4% |
ReShape Lifesciences Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $3.20 M(+0.4%) |
| June 2024 | - | $3.19 M(-5.5%) |
| Mar 2024 | - | $3.38 M(-9.7%) |
| Dec 2023 | $20.19 M(-40.4%) | $3.74 M(-14.9%) |
| Sept 2023 | - | $4.39 M(-15.6%) |
| June 2023 | - | $5.20 M(-24.1%) |
| Mar 2023 | - | $6.86 M(+0.3%) |
| Dec 2022 | $33.88 M(-4.8%) | $6.83 M(-2.0%) |
| Sept 2022 | - | $6.97 M(-35.1%) |
| June 2022 | - | $10.75 M(+15.2%) |
| Mar 2022 | - | $9.33 M(+15.7%) |
| Dec 2021 | $35.58 M(+90.1%) | $8.06 M(-52.9%) |
| Sept 2021 | - | $17.12 M(+192.4%) |
| June 2021 | - | $5.86 M(+28.9%) |
| Mar 2021 | - | $4.54 M(-6.3%) |
| Dec 2020 | $18.72 M(-25.7%) | $4.84 M(+8.8%) |
| Sept 2020 | - | $4.45 M(+16.1%) |
| June 2020 | - | $3.83 M(-31.3%) |
| Mar 2020 | - | $5.58 M(+17.8%) |
| Dec 2019 | $25.19 M(+0.8%) | $4.74 M(-23.7%) |
| Sept 2019 | - | $6.22 M(-19.8%) |
| June 2019 | - | $7.75 M(+19.7%) |
| Mar 2019 | - | $6.48 M(+44.3%) |
| Dec 2018 | $24.98 M(-11.7%) | $4.49 M(-15.0%) |
| Sept 2018 | - | $5.28 M(-17.2%) |
| June 2018 | - | $6.38 M(-27.8%) |
| Mar 2018 | - | $8.84 M(+2.5%) |
| Dec 2017 | $28.29 M(+22.2%) | $8.62 M(+51.1%) |
| Sept 2017 | - | $5.71 M(-17.5%) |
| June 2017 | - | $6.91 M(-2.0%) |
| Mar 2017 | - | $7.05 M(+68.6%) |
| Dec 2016 | $23.15 M(-17.4%) | $4.18 M(-9.4%) |
| Sept 2016 | - | $4.62 M(-31.9%) |
| June 2016 | - | $6.78 M(-10.5%) |
| Mar 2016 | - | $7.57 M(-0.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2015 | $28.03 M(+9.5%) | $7.63 M(+26.1%) |
| Sept 2015 | - | $6.05 M(-18.1%) |
| June 2015 | - | $7.39 M(+6.1%) |
| Mar 2015 | - | $6.96 M(+14.4%) |
| Dec 2014 | $25.59 M(+3.5%) | $6.09 M(+8.8%) |
| Sept 2014 | - | $5.59 M(-23.9%) |
| June 2014 | - | $7.35 M(+12.1%) |
| Mar 2014 | - | $6.56 M(+2.9%) |
| Dec 2013 | $24.73 M(+9.3%) | $6.37 M(+6.8%) |
| Sept 2013 | - | $5.97 M(-1.7%) |
| June 2013 | - | $6.07 M(-3.9%) |
| Mar 2013 | - | $6.32 M(-6.5%) |
| Dec 2012 | $22.63 M(-10.4%) | $6.76 M(+21.3%) |
| Sept 2012 | - | $5.57 M(+16.8%) |
| June 2012 | - | $4.77 M(-13.6%) |
| Mar 2012 | - | $5.52 M(-29.9%) |
| Dec 2011 | $25.26 M(+56.1%) | $7.89 M(+10.5%) |
| Sept 2011 | - | $7.13 M(+32.6%) |
| June 2011 | - | $5.38 M(+10.8%) |
| Mar 2011 | - | $4.86 M(+34.2%) |
| Dec 2010 | $16.18 M(-33.2%) | $3.62 M(-11.6%) |
| Sept 2010 | - | $4.09 M(-0.5%) |
| June 2010 | - | $4.11 M(-5.4%) |
| Mar 2010 | - | $4.35 M(-13.3%) |
| Dec 2009 | $24.21 M(-33.2%) | $5.02 M(-31.0%) |
| Sept 2009 | - | $7.27 M(+16.5%) |
| June 2009 | - | $6.23 M(+9.4%) |
| Mar 2009 | - | $5.70 M(-11.9%) |
| Dec 2008 | $36.27 M(+29.4%) | $6.47 M(-35.7%) |
| Sept 2008 | - | $10.06 M(-10.4%) |
| June 2008 | - | $11.23 M(+31.8%) |
| Mar 2008 | - | $8.52 M(-1.8%) |
| Dec 2007 | $28.03 M(+54.7%) | $8.67 M(+34.4%) |
| Sept 2007 | - | $6.45 M |
| Dec 2006 | $18.12 M(+62.5%) | - |
| Dec 2005 | $11.15 M | - |
FAQ
- What is ReShape Lifesciences annual total operating expenses?
- What is the all time high annual operating expenses for ReShape Lifesciences?
- What is ReShape Lifesciences annual operating expenses year-on-year change?
- What is ReShape Lifesciences quarterly total operating expenses?
- What is the all time high quarterly operating expenses for ReShape Lifesciences?
- What is ReShape Lifesciences quarterly operating expenses year-on-year change?
What is ReShape Lifesciences annual total operating expenses?
The current annual operating expenses of RSLS is $20.19 M
What is the all time high annual operating expenses for ReShape Lifesciences?
ReShape Lifesciences all-time high annual total operating expenses is $36.27 M
What is ReShape Lifesciences annual operating expenses year-on-year change?
Over the past year, RSLS annual total operating expenses has changed by -$13.69 M (-40.42%)
What is ReShape Lifesciences quarterly total operating expenses?
The current quarterly operating expenses of RSLS is $3.20 M
What is the all time high quarterly operating expenses for ReShape Lifesciences?
ReShape Lifesciences all-time high quarterly total operating expenses is $17.12 M
What is ReShape Lifesciences quarterly operating expenses year-on-year change?
Over the past year, RSLS quarterly total operating expenses has changed by -$1.19 M (-27.12%)